NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free GOVX Stock Alerts $1.61 -0.11 (-6.40%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.7350-Day Range$1.40▼$2.0152-Week Range$1.38▼$10.24Volume254,805 shsAverage Volume75,457 shsMarket Capitalization$3.72 millionP/E RatioN/ADividend YieldN/APrice Target$120.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get GeoVax Labs alerts: Email Address GeoVax Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7,353.4% Upside$120.00 Price TargetShort InterestHealthy0.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.99 out of 5 stars 3.5 Analyst's Opinion Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeoVax Labs has received no research coverage in the past 90 days.Read more about GeoVax Labs' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.86% of the float of GeoVax Labs has been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently increased by 193.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GOVX. Previous Next 0.6 News and Social Media Coverage Search Interest4 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions.Read more about GeoVax Labs' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GeoVax Labs' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About GeoVax Labs Stock (NASDAQ:GOVX)GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More GOVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVX Stock News HeadlinesMay 29, 2024 | finance.yahoo.comGeoVax to Present at BIO International Convention 2024May 17, 2024 | finance.yahoo.comGeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-MarketMay 15, 2024 | msn.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comGOVX Stock Earnings: Geovax Labs Beats EPS for Q1 2024May 14, 2024 | finance.yahoo.comGeoVax Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 5, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineMarch 28, 2024 | globenewswire.comGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressMarch 22, 2024 | investing.comGeoVax Labs Inc (GOVX)March 12, 2024 | globenewswire.comGeoVax to Present at the 36th Annual Roth ConferenceMarch 6, 2024 | globenewswire.comGeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing SystemMarch 2, 2024 | finance.yahoo.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Reports 2023 Year-End Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comGeoVax Reports 2023 Year-End Financial Results and Provides Business UpdateFebruary 28, 2024 | benzinga.comEarnings Outlook For Geovax LabsFebruary 24, 2024 | msn.comGeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78February 23, 2024 | msn.comInMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are BuyingFebruary 22, 2024 | finance.yahoo.comGeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024February 22, 2024 | globenewswire.comGeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024February 20, 2024 | finance.yahoo.comGeoVax Labs, Inc. (GOVX)February 20, 2024 | uk.finance.yahoo.comGeoVax to Present at the 2024 BIO CEO & Investor ConferenceFebruary 19, 2024 | finance.yahoo.comGeoVax to Present at the 2024 BIO CEO & Investor ConferenceFebruary 19, 2024 | globenewswire.comGeoVax to Present at the 2024 BIO CEO & Investor ConferenceJanuary 29, 2024 | msn.comGeoVax Labs to effect 1-for-15 reverse stock split to regain compliance with Nasdaq ruleJanuary 8, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, OncologyJanuary 8, 2024 | finance.yahoo.comGeoVax Appoints Dr. Marc Pipas as Executive Medical Director, OncologySee More Headlines Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/08/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GOVX CUSIPN/A CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$120.00 High Stock Price Target$120.00 Low Stock Price Target$120.00 Potential Upside/Downside+7,353.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-346.15% Return on Assets-221.83% Debt Debt-to-Equity RatioN/A Current Ratio0.87 Quick Ratio0.87 Sales & Book Value Annual Sales$80,000.00 Price / Sales46.49 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.50Miscellaneous Outstanding Shares2,310,000Free Float2,176,000Market Cap$3.72 million OptionableNot Optionable Beta2.77 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. David Alan Dodd (Age 74)Chairman, President & CEO Comp: $384.2kDr. Mark J. Newman Ph.D. (Age 69)Chief Scientific Officer Comp: $291.5kDr. Kelly T. McKee Jr. (Age 73)M.D., M.P.H., Chief Medical Officer Comp: $361.03kDr. Harriet Latham Robinson Ph.D. (Age 86)Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board Mr. Thomas O'BrienVice President of Quality Systems & ComplianceMr. Jeffrey WelchHead of Process Development & Manufacturing OperationsDr. Valerie C. Montgomery Rice FACOG (Age 61)M.D., Special Advisor to the Chairman & CEO and Board of Directors Mr. John NilesHead of Commercial OperationsDr. John W. Sharkey Ph.D. (Age 68)Vice President of Business Development More ExecutivesKey CompetitorsEdesa BiotechNASDAQ:EDSAPurple BiotechNASDAQ:PPBTFlora GrowthNASDAQ:FLGCMonopar TherapeuticsNASDAQ:MNPRGalectoNASDAQ:GLTOView All CompetitorsInsidersDavid A DoddBought 520 shares on 2/21/2024Total: $1,118.00 ($2.15/share)Kelly T Jr. MckeeBought 462 shares on 12/22/2023Total: $2,494.80 ($5.40/share)Kelly T Jr. MckeeBought 643 shares on 9/25/2023Total: $5,015.40 ($7.80/share)David A DoddBought 2,339 shares on 8/25/2023Total: $19,998.45 ($8.55/share)Mark ReynoldsBought 666 shares on 8/18/2023Total: $5,194.80 ($7.80/share)View All Insider Transactions GOVX Stock Analysis - Frequently Asked Questions Should I buy or sell GeoVax Labs stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOVX shares. View GOVX analyst ratings or view top-rated stocks. What is GeoVax Labs' stock price target for 2024? 1 brokers have issued 1 year price targets for GeoVax Labs' shares. Their GOVX share price targets range from $120.00 to $120.00. On average, they expect the company's stock price to reach $120.00 in the next twelve months. This suggests a possible upside of 7,353.4% from the stock's current price. View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts. How have GOVX shares performed in 2024? GeoVax Labs' stock was trading at $5.4150 at the beginning of the year. Since then, GOVX shares have decreased by 70.3% and is now trading at $1.61. View the best growth stocks for 2024 here. Are investors shorting GeoVax Labs? GeoVax Labs saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 21,400 shares, an increase of 193.2% from the April 30th total of 7,300 shares. Based on an average daily volume of 57,300 shares, the short-interest ratio is currently 0.4 days. Currently, 0.9% of the company's shares are short sold. View GeoVax Labs' Short Interest. When is GeoVax Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our GOVX earnings forecast. How were GeoVax Labs' earnings last quarter? GeoVax Labs, Inc. (NASDAQ:GOVX) announced its earnings results on Tuesday, May, 14th. The company reported ($2.47) earnings per share (EPS) for the quarter. When did GeoVax Labs' stock split? GeoVax Labs shares reverse split on the morning of Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOVX) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.